Novel approaches in the treatment of systemic mastocytosis

Alfonso Quintas-Cardama, Ahmed Aribi, Jorge Cortes, Francis J. Giles, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journalReview article

Abstract

In the absence of curative options, therapy for aggressive forms of systemic mastocytosis (SM) has relied in the use of cytoreductive agents, mainly interferon-α (IFN-α) and cladribine. However, responses are transient and only occur in a subset of patients. Gain-of-function mutations at codon 816 of the KIT protooncogene lead to constitutively active Kit receptor molecules, which are central to the pathogenesis of SM. Recent advances in the understanding of the molecular underpinnings of SM have led to the development of small molecules targeting mutant Kit tyrosine kinase isoforms that significantly have widened the range of therapeutic options for patients with SM. Some of these promising agents, such as dasatinib, AMN107, and PKC412, currently are under investigation in clinical trials whereas, others are at different stages of preclinical development. In addition, monoclonal antibodies directed to neoplastic mast cell-restricted surface antigens constitute a viable option for the treatment of SM that warrants further investigation.

Original languageEnglish (US)
Pages (from-to)1429-1439
Number of pages11
JournalCancer
Volume107
Issue number7
DOIs
StatePublished - Oct 1 2006
Externally publishedYes

Fingerprint

Systemic Mastocytosis
4'-N-benzoylstaurosporine
Cladribine
Therapeutics
Surface Antigens
Mast Cells
Codon
Protein-Tyrosine Kinases
Interferons
Protein Isoforms
Monoclonal Antibodies
Clinical Trials
Mutation

Keywords

  • Kit
  • Review
  • Systemic mastocytosis
  • Therapy
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Quintas-Cardama, A., Aribi, A., Cortes, J., Giles, F. J., Kantarjian, H., & Verstovsek, S. (2006). Novel approaches in the treatment of systemic mastocytosis. Cancer, 107(7), 1429-1439. https://doi.org/10.1002/cncr.22187

Novel approaches in the treatment of systemic mastocytosis. / Quintas-Cardama, Alfonso; Aribi, Ahmed; Cortes, Jorge; Giles, Francis J.; Kantarjian, Hagop; Verstovsek, Srdan.

In: Cancer, Vol. 107, No. 7, 01.10.2006, p. 1429-1439.

Research output: Contribution to journalReview article

Quintas-Cardama, A, Aribi, A, Cortes, J, Giles, FJ, Kantarjian, H & Verstovsek, S 2006, 'Novel approaches in the treatment of systemic mastocytosis', Cancer, vol. 107, no. 7, pp. 1429-1439. https://doi.org/10.1002/cncr.22187
Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S. Novel approaches in the treatment of systemic mastocytosis. Cancer. 2006 Oct 1;107(7):1429-1439. https://doi.org/10.1002/cncr.22187
Quintas-Cardama, Alfonso ; Aribi, Ahmed ; Cortes, Jorge ; Giles, Francis J. ; Kantarjian, Hagop ; Verstovsek, Srdan. / Novel approaches in the treatment of systemic mastocytosis. In: Cancer. 2006 ; Vol. 107, No. 7. pp. 1429-1439.
@article{bf4a1265d37b424ebce4b04920da24b6,
title = "Novel approaches in the treatment of systemic mastocytosis",
abstract = "In the absence of curative options, therapy for aggressive forms of systemic mastocytosis (SM) has relied in the use of cytoreductive agents, mainly interferon-α (IFN-α) and cladribine. However, responses are transient and only occur in a subset of patients. Gain-of-function mutations at codon 816 of the KIT protooncogene lead to constitutively active Kit receptor molecules, which are central to the pathogenesis of SM. Recent advances in the understanding of the molecular underpinnings of SM have led to the development of small molecules targeting mutant Kit tyrosine kinase isoforms that significantly have widened the range of therapeutic options for patients with SM. Some of these promising agents, such as dasatinib, AMN107, and PKC412, currently are under investigation in clinical trials whereas, others are at different stages of preclinical development. In addition, monoclonal antibodies directed to neoplastic mast cell-restricted surface antigens constitute a viable option for the treatment of SM that warrants further investigation.",
keywords = "Kit, Review, Systemic mastocytosis, Therapy, Tyrosine kinase inhibitors",
author = "Alfonso Quintas-Cardama and Ahmed Aribi and Jorge Cortes and Giles, {Francis J.} and Hagop Kantarjian and Srdan Verstovsek",
year = "2006",
month = "10",
day = "1",
doi = "10.1002/cncr.22187",
language = "English (US)",
volume = "107",
pages = "1429--1439",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Novel approaches in the treatment of systemic mastocytosis

AU - Quintas-Cardama, Alfonso

AU - Aribi, Ahmed

AU - Cortes, Jorge

AU - Giles, Francis J.

AU - Kantarjian, Hagop

AU - Verstovsek, Srdan

PY - 2006/10/1

Y1 - 2006/10/1

N2 - In the absence of curative options, therapy for aggressive forms of systemic mastocytosis (SM) has relied in the use of cytoreductive agents, mainly interferon-α (IFN-α) and cladribine. However, responses are transient and only occur in a subset of patients. Gain-of-function mutations at codon 816 of the KIT protooncogene lead to constitutively active Kit receptor molecules, which are central to the pathogenesis of SM. Recent advances in the understanding of the molecular underpinnings of SM have led to the development of small molecules targeting mutant Kit tyrosine kinase isoforms that significantly have widened the range of therapeutic options for patients with SM. Some of these promising agents, such as dasatinib, AMN107, and PKC412, currently are under investigation in clinical trials whereas, others are at different stages of preclinical development. In addition, monoclonal antibodies directed to neoplastic mast cell-restricted surface antigens constitute a viable option for the treatment of SM that warrants further investigation.

AB - In the absence of curative options, therapy for aggressive forms of systemic mastocytosis (SM) has relied in the use of cytoreductive agents, mainly interferon-α (IFN-α) and cladribine. However, responses are transient and only occur in a subset of patients. Gain-of-function mutations at codon 816 of the KIT protooncogene lead to constitutively active Kit receptor molecules, which are central to the pathogenesis of SM. Recent advances in the understanding of the molecular underpinnings of SM have led to the development of small molecules targeting mutant Kit tyrosine kinase isoforms that significantly have widened the range of therapeutic options for patients with SM. Some of these promising agents, such as dasatinib, AMN107, and PKC412, currently are under investigation in clinical trials whereas, others are at different stages of preclinical development. In addition, monoclonal antibodies directed to neoplastic mast cell-restricted surface antigens constitute a viable option for the treatment of SM that warrants further investigation.

KW - Kit

KW - Review

KW - Systemic mastocytosis

KW - Therapy

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=33749627742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749627742&partnerID=8YFLogxK

U2 - 10.1002/cncr.22187

DO - 10.1002/cncr.22187

M3 - Review article

C2 - 16948123

AN - SCOPUS:33749627742

VL - 107

SP - 1429

EP - 1439

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -